HLS Therapeutics Inc
TSX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
HLS Therapeutics Inc
Cash & Cash Equivalents
HLS Therapeutics Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
HLS Therapeutics Inc
TSX:HLS
|
Cash & Cash Equivalents
$11.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
M
|
Manitex Capital Inc
XTSX:MNX
|
Cash & Cash Equivalents
CA$800
|
CAGR 3-Years
-86%
|
CAGR 5-Years
-67%
|
CAGR 10-Years
-55%
|
|
|
G
|
Greenrise Global Brands Inc
CNSX:XCX
|
Cash & Cash Equivalents
€1.3k
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
-37%
|
|
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
See Also
What is HLS Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
11.7m
USD
Based on the financial report for Dec 31, 2025, HLS Therapeutics Inc's Cash & Cash Equivalents amounts to 11.7m USD.
What is HLS Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-7%
Over the last year, the Cash & Cash Equivalents growth was -33%. The average annual Cash & Cash Equivalents growth rates for HLS Therapeutics Inc have been -17% over the past three years , -11% over the past five years , and -7% over the past ten years .
